High-Dose Continuous Infusion Plus Pulse Interleukin-2 and Famotidine in Melanoma-Reference-Cited by-同舟云学术

High-Dose Continuous Infusion Plus Pulse Interleukin-2 and Famotidine in Melanoma

Published:2004-12 Issue:6 Volume:19 Page:770-775
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Quan Walter¹,Ramirez Maria²,Taylor W. Chris²,Vinogradov Mikhail²,Khan Nawazish²,Jackson Shawn³

Affiliation:

1. Division of Medical Oncology and Hematology, Medical College of Ohio, Toledo, OH

2. Department of Medicine, East Carolina University School of Medicine, Greenville, NC

3. Department of Dermatology, University of Texas Medical Branch, Galveston, TX

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2004.19.770

Reference32 articles.

1. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

2. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Disturbances of Phosphate Homeostasis;Seldin and Giebisch's The Kidney;2013

2. Outpatient Intravenous Interleukin-2 with Famotidine Has Activity in Metastatic Melanoma;Cancer Biotherapy and Radiopharmaceuticals;2012-09

3. Pulse Infusion Interleukin-2 with Famotidine and Cyclophosphamide Has Activity in Previously Treated Metastatic Melanoma;Cancer Biotherapy and Radiopharmaceuticals;2010-04

4. Metastatic Kidney Cancer: Treatment with Infusional Interleukin-2 Plus Famotidine;Methods of Cancer Diagnosis, Therapy, and Prognosis;2009-10-10

5. High-Dose Intensity Pulse Interleukin-2 with Famotidine in Metastatic Kidney Cancer;Cancer Biotherapy and Radiopharmaceuticals;2009-04